Yamo Pharma Begins Patient Enrollment In Phase 2 Study Of L1-79 In Autism Spectrum Disorder
Yamo Pharmaceuticals, A Clinical Stage Pharmaceutical Company, Announced That The First Patient Has Been Treated In A Phase 2 Study Of L1-79 In Adolescents And Young Adults With Autism Spectrum Disorder (Asd) At Six Us Research Centers Of Excellence. L1-79 Is A Tyrosine Hydroxylase Inhibitor Designed To Improve The Socialization And Communication Symptoms By Modulating The Catecholaminergic Pathways Implicated In Asd.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!